CDK4/6 Inhibitors clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sorry, not currently recruiting here
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
Orange, California and other locations
Our lead scientists for CDK4/6 Inhibitors research studies include Ritesh Parajuli.
Last updated: